BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 17484926)

  • 21. Is full bilateral retroperitoneal lymph node dissection always necessary for postchemotherapy residual tumor?
    Beck SD; Foster RS; Bihrle R; Donohue JP; Einhorn LH
    Cancer; 2007 Sep; 110(6):1235-40. PubMed ID: 17665498
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Management of clinical stage I nonseminomatous germ cell testicular cancer.
    Choueiri TK; Stephenson AJ; Gilligan T; Klein EA
    Urol Clin North Am; 2007 May; 34(2):137-48; abstract viii. PubMed ID: 17484919
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Viable malignant germ cell tumor in the postchemotherapy retroperitoneal lymph node dissection specimen: can it be predicted using clinical parameters?
    Spiess PE; Brown GA; Pisters LL; Liu P; Tu SM; Evans JG; Kamat AM; Black P; Tannir NM
    Cancer; 2006 Oct; 107(7):1503-10. PubMed ID: 16944534
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Significance of elevated preoperative alpha-fetoprotein in postchemotherapy residual tumor resection for the disseminated germ cell tumors.
    Kobayashi T; Kawakita M; Terachi T; Habuchi T; Ogawa O; Kamoto T
    J Surg Oncol; 2006 Dec; 94(7):619-23. PubMed ID: 17111392
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recurrence in nonseminomatous germ cell testis tumor patients with no viable tumor at postchemotherapy retroperitoneal lymph node dissection.
    Spiess PE; Tannir NM; Brown GA; Liu P; Tu SM; Evans JG; Pisters LL
    Urology; 2007 Dec; 70(6):1173-8. PubMed ID: 18158041
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Distribution of nodal metastases after chemotherapy in nonseminomatous testis cancer: a possible indication for limited dissection.
    Ehrlich Y; Yossepowitch O; Kedar D; Baniel J
    BJU Int; 2006 Jun; 97(6):1221-4. PubMed ID: 16686715
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Viable germ cell tumor at postchemotherapy retroperitoneal lymph node dissection: can we predict patients at risk of disease progression?
    Spiess PE; Tannir NM; Tu SM; Brown GA; Liu P; Kamat AM; Wood CG; Evans JG; Pisters LL
    Cancer; 2007 Dec; 110(12):2700-8. PubMed ID: 17948916
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predicting teratoma in the retroperitoneum in men undergoing post-chemotherapy retroperitoneal lymph node dissection.
    Carver BS; Bianco FJ; Shayegan B; Vickers A; Motzer RJ; Bosl GJ; Sheinfeld J
    J Urol; 2006 Jul; 176(1):100-3; discussion 103-4. PubMed ID: 16753380
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pathologic findings and clinical outcome of patients undergoing retroperitoneal lymph node dissection after multiple chemotherapy regimens for metastatic testicular germ cell tumors.
    Eggener SE; Carver BS; Loeb S; Kondagunta GV; Bosl GJ; Sheinfeld J
    Cancer; 2007 Feb; 109(3):528-35. PubMed ID: 17177200
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Surgery for testicular cancer: indication, results and technical aspects.
    Khouni H; Ghozzi S; Ramzi K; Smaali CH; Majed H; Ben Rais N
    Tunis Med; 2005 Dec; 83 Suppl 12():78-83. PubMed ID: 16430075
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Postchemotherapy retroperitoneal lymph node dissection in advanced germ cell tumours of the testis.
    Heidenreich A; Thüer D; Polyakov S
    Eur Urol; 2008 Feb; 53(2):260-72. PubMed ID: 18045770
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Retroperitoneal lymph node dissection after chemotherapy.
    Winter C; Raman JD; Sheinfeld J; Albers P
    BJU Int; 2009 Nov; 104(9 Pt B):1404-12. PubMed ID: 19840021
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical outcome of retroperitoneal lymph node dissection after induction chemotherapy for metastatic non-seminomatous germ cell tumors.
    Muramaki M; Hara I; Miyake H; Yamada Y; Okada H; Kamidono S
    Int J Urol; 2004 Sep; 11(9):763-7. PubMed ID: 15379941
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Retroperitoneal lymph node dissection in patients with high risk testicular cancer.
    Williams SB; McDermott DW; Dock W; Bahnson E; Berry AM; Steele GS; Richie JP
    J Urol; 2009 May; 181(5):2097-101; discussion 2101-2. PubMed ID: 19286227
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Outcomes of postchemotherapy retroperitoneal lymph node dissection following high-dose chemotherapy with stem cell transplantation.
    Cary C; Pedrosa JA; Jacob J; Beck SD; Rice KR; Einhorn LH; Foster RS
    Cancer; 2015 Dec; 121(24):4369-75. PubMed ID: 26371446
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Laparoscopic retroperitoneal lymph node dissection: does it still have a role in the management of clinical stage I nonseminomatous testis cancer? A European perspective.
    Rassweiler JJ; Scheitlin W; Heidenreich A; Laguna MP; Janetschek G
    Eur Urol; 2008 Nov; 54(5):1004-15. PubMed ID: 18722704
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Primary retroperitoneal lymph node dissection in patients with clinical stage IS testis cancer.
    Williams SB; Steele GS; Richie JP
    J Urol; 2009 Dec; 182(6):2716-20. PubMed ID: 19836777
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Retroperitoneal lymph node dissection after chemotherapy for germ cell tumours: is a full bilateral template always necessary?
    Steiner H; Peschel R; Bartsch G
    BJU Int; 2008 Aug; 102(3):310-4. PubMed ID: 18325053
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reoperative retroperitoneal surgery.
    Sheinfeld J; Sogani P
    Urol Clin North Am; 2007 May; 34(2):227-33; abstract x. PubMed ID: 17484927
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Significance of primary tumor size and preorchiectomy serum tumor marker level in predicting pathologic stage at retroperitoneal lymph node dissection in clinical Stage A nonseminomatous germ cell tumors.
    Beck SD; Foster RS; Bihrle R; Donohue JP
    Urology; 2007 Mar; 69(3):557-9. PubMed ID: 17382165
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.